FDA says Elan, Bristol-Myers antibiotic under review

11/15/2007 | Bloomberg · CNNMoney

The FDA said it is conducting a safety review of Maxipime, an antibiotic marketed by Elan Corp. and Bristol-Myers Squibb Co., to address a published study linking the injectable drug to an increased risk of death. The agency said it is working with Bristol-Myers to investigate the safety of Maxipime, which has been approved for use in treating infections, such as pneumonia and urinary tract infections.

View Full Article in:

Bloomberg · CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC